Innovent to Present Mazdutide Study Results at ADA's 84th Scientific Sessions

Innovent Biologics, Inc., a leading biopharmaceutical company specializing in developing, manufacturing, and commercializing high-quality medicines for various diseases, has announced it will present multiple clinical study results of its drug, mazdutide, at the American Diabetes Association's 84th Scientific Sessions. The event will be held in Orlando from June 21 to June 24, 2024.

The presentation will include results from the first phase 3 study of mazdutide in Chinese adults with obesity and overweight, known as the GLORY-1 study. Additionally, an exploratory analysis of GLORY-1 on liver steatosis, and a Phase 2 study of mazdutide 9 mg in adults with obesity will be shared.

One of the key oral presentations, titled "Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)," will be delivered by Dr. Linong Ji from Peking University People's Hospital. This presentation is scheduled for June 23 at 1:30 PM EST. The exploratory analysis on liver steatosis will be presented in a poster format, and another poster will detail the Phase 2 study of mazdutide 9 mg in Chinese adults with a BMI of 30 kg/m2 or more.

Dr. Lei Qian, Vice President of Clinical Development at Innovent, expressed enthusiasm about sharing the GLORY-1 results at the ADA scientific sessions. Dr. Qian highlighted that mazdutide is the first GLP-1R/GCGR dual agonist to succeed in a Phase 3 registration study for overweight and obese individuals. He also noted that promising results from a Phase 2 study involving mazdutide 9 mg in Chinese adults with moderate-to-severe obesity would be presented, while the Phase 3 GLORY-2 study is ongoing. Mazdutide aims to offer a personalized, effective, and safe weight management option for people with varying levels of obesity.

Mazdutide, also known as OXM3, is a GLP-1R and GCGR dual agonist developed under an exclusive license agreement with Eli Lilly and Company for commercialization in China. This drug acts as a mammalian oxyntomodulin analogue, promoting insulin secretion, lowering blood glucose, and reducing body weight. Additionally, it may enhance energy expenditure and improve hepatic fat metabolism. Clinical studies have shown that mazdutide significantly contributes to weight loss and glucose lowering, along with improvements in various cardio-metabolic indicators.

Currently, five Phase 3 studies of mazdutide are in progress involving Chinese adults with overweight or obesity (GLORY-1 and GLORY-2) and type 2 diabetes (DREAMS-1, DREAMS-2, and DREAMS-3). Both GLORY-1 and DREAMS-2 have met their primary endpoints. In February 2024, the first New Drug Application (NDA) for mazdutide was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for chronic weight management in adults with obesity or overweight.

Innovent, founded in 2011, strives to offer affordable, high-quality biologics and has developed innovative treatments for intractable diseases such as cancer, cardiovascular and metabolic disorders, autoimmune diseases, and eye conditions. The company has ten marketed products, four new drug applications under NMPA review, four assets in Phase III or pivotal clinical trials, and 18 molecules in early clinical stages. Innovent collaborates with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center.

Guided by its motto, "Start with Integrity, Succeed through Action," Innovent upholds the highest industry standards and works to ensure that top-quality pharmaceutical drugs are widely accessible.